Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-06-06
2010-02-02
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S366000, C548S148000, C546S270100
Reexamination Certificate
active
07655676
ABSTRACT:
Use of the compound of formula (I) and the pharmaceutically acceptable addition salts thereof for the manufacture of a medicament for topical treatment or 5 prevention of acne formula (I) wherein: R represents methoxymethyl, R1 represents methyl, Rz represents methyl, Y represents the group formula (II) The compound of formula (I) and the pharmaceutically acid addition salts thereof show selective activity againstpropionibacterium acneand are suitable for use in a method of treatment or prevention of acne.
REFERENCES:
patent: 5139778 (1992-08-01), Selva et al.
patent: 5200429 (1993-04-01), Sato et al.
patent: 5380763 (1995-01-01), Sato et al.
patent: 5599791 (1997-02-01), Tavecchia et al.
patent: 6008225 (1999-12-01), Lociuro et al.
patent: 6143739 (2000-11-01), Seneci et al.
patent: 0494078 (1992-07-01), None
patent: 0577356 (1994-01-01), None
patent: 0565567 (1995-01-01), None
patent: WO 92/12172 (1992-07-01), None
Clark,Practitioner1993; 237:160-164.
Cunliffe, “The sebaceous gland and acne—40 years on,”Dermatology1998; 9-15.
Eady, “Bacterial resistance in acne,”Dermatology1998; 196:1:59-66.
Kelly, “Acne and related disorders,” In: Sams JR., Lynch WM., Lynch PJ., eds.Principles and practice of dermatology. 2nded. New York, NY: Churchill Livingstone. 1996; 801-808.
Lancaster Catalog, pp. 589, 590, 1991 Windhan, N. H.
Toyoda et al., “An overview of topical antibiotics for acne treatment,”Dermatology1998; 196: 1:130-4.
Wu et al., “Role of anxiety and anger in acne patients: a relationship with the severity of the disorder,”J Am Acad Dermatol1988; 18: 325-333.
Berson DS, Shalita AR. The treatment of acne: the role of combination therapies. J Am Acad Dermatol 1995; 32: 531-541.
Crawford WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance inCorynebacterium acnes. J Invest Dermatol 1979; 72: 187-190.
Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic-treated patients: association with therapeutic failure. Br J Dermatol 1989; 121:51-7.
Ebling FJ., Cunliffe WJ. Disorders of sebaceous glands. In: Rook A., Wilkinson DS., Ebling FJ., Champion RH., Burton JL, eds. Textbook of Dermatology. vol. III. Boston: Blackwell Scientific, 1992; 1699-744.
Espersen F. Resistance to antibiotics used in dermatology practice. BR J Dermatol 1998; 139 (53): 4-8.
Hurwitz S. The combined effect of vitamin A acid and benzoyl peroxide in the treatment of acne. Cutis 1976; 17: 585-590.
Ingram E, Holland KT, Gowland C, et al. Studies of the extracellular proteolytic activity produced byPropionibacterium acnes. J Appl Bacteriol 1983; 54:263-271.
Koo JYM, Smith LL. Psychologic aspects of acne. Pediatr Dermatol 1991; 8: 185-88.
Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol 1995; 32: S26-S30.
Leyden JJ, McGinley KJ, Cavalieri S et al.Propionibacterium acnesresistance in acne patients. J Am Acad Dermatol 1983; 8: 41-5.
Leyden JJ. New understanding of the pathogenesis of acne. J Am Acad Dermatol 1995; 32: S15-S25.
McEvoy GK, ed. AHFS drug Information. Bethesda, MD: American Society of Health System Pharmacists; 1996; pp. 374 and 2522.
Nord CE. Treating acne with antibiotics leads to antibiotic resistance. Proceedings of the101st Annual Meeting of ASM, Orlando May 2001.
Panzer, J.D. et al. “Acne Treatment: A Comparative Efficacy Trial of Clindamycin and Tetracycline”, Cutis, Excerpta Medica 19(1): 109-111 (Jan. 1977).
Puhvel SM, Sakamoto M. An in vitro evaluation of the inflammatory effect of purified comedonal components in human skin. J Invest Dermatol 1977; 69:401-406.
Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ et al. Phenotypic and genotypic characterization of antibiotic-resistantPropionibacterium acnesisolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46.
Selva, E. et al. “Antibiotic GE 2270 a: a novel inhibitor of bacgerial protein synthesis. I. Isolation and characterization.” J. Antibiotics (Tokyo) 44(7): 693-701 (1991).
Siegle RJ, Fekety R, Sarbone PD, et al. Effects of topical clindamycin on intestinal microflora in patients with acne. J Am Acad Dermatol 1986; 15: 180-5.
Sykes NL, Webster GF. Acne: a review of optimum treatment. Drugs 1994; 48: 59-70.
Walters CE, Ingham E, Eady EA, Cove JH, Kearney JN, Cunliffe WJ. In vitro modulation of keratinocyte-derived interleukin-1 alpha (IL-1 alpha) and peripheral blood mononuclear cell-derived IL-1 beta release in response to cutaneous commensal microorganisms. Infect Immun 1995; 63:1223-28.
Webster GF. Inflammation inAcne vulgaris. J Am Acad Dermatol 1995; 33:247-253.
Winston MH., Shalita AR.Acne vulgaris: pathogenesis and treatment. Pediatr Clinic North Am 1991; 38:889-903.
Cavaleri Marco
Jabes Daniela
Malabarba Adriano
Mosconi Giorgio
Romano Gabriela
Carter Kendra D
Naicons S.C.A.R.L.
Nixon & Vanderhye P.C.
Wang Shengjun
LandOfFree
Use of amide derivative of GE 2270 factor A 3 for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of amide derivative of GE 2270 factor A 3 for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of amide derivative of GE 2270 factor A 3 for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197006